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Summary
The aim of this study was to analyse the accuracy of scintigraphic and gamma probe sentinel node (SN)
localization in breast cancer patients who have been submitted to neoadjuvant chemotherapy (NC).
Seventy-six patients with single breast cancer were included in the study, and were classified into two
groups. Group 1 consisted of 40 women who had received NC, and Group 2 consisted of 36 women who
did not receive NC. All patients received 111 MBq (3 mCi) of 99Tcm-nanocolloid in 3 ml, by peritumoural
injection. Anterior and lateral thoracic scans were obtained 2 h post-injection. The following day (18±24 h
post-injection) the patients underwent surgery and sentinel nodes were localized by using a gamma probe.
Complete axillary lymph node dissection was performed in all patients. Histological analysis included
haematoxylin±eosin in all cases and immunohistochemistry in 10 cases. In Group 1, SNs were localized in
36/40 patients, histological analysis was performed in 34 and there were four false negatives (22%). In
Group 2, SNs were localized in 32/36 patients, histological analysis was performed in 29 and there were
two false negatives (9%). Predictive negative values were 78% and 90% in Groups 1 and 2, respectively. In
summary, sentinel node localization in breast cancer patients submitted to previous neoadjuvant
chemotherapy is less accurate than in patients who do not receive this therapy. The procedure is not
sufficiently accurate to localize the sentinel node, thus it cannot be recommended in these patients. (# 2001
Lippincott Williams & Wilkins)
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Introduction
Detection and analysis of sentinel nodes
The histological status of axillary lymph nodes is one of
the most important prognostic indicators in breast cancer
patients [1]. Between 70% and 80% of these patients will
have completely negative surgical axillary lymph node
examination, and 3±12% will develop lymphoedema
post-surgery.
Lymphoscintigraphy and radioguided biopsy of the
sentinel node (SN) is a useful method for staging the
regional drainage pathway in breast cancer. The sentinel
lymph node is the first to receive drainage from the
tumour. It can be detected by using different techniques.
Once identified, the SN can be analysed and the
involvement of other axillary lymph nodes can be
inferred from its status. With this information it is
possible to avoid a regional axillary lymph node
dissection. If haematoxylin and eosin (H&E) staining
and/or immunohistochemistry do not show an involve-
ment of the SN, the probability of node involvement
beyond the SN is less than 0.1% [2].
Some authors have reported the results of sentinel
node mapping and surgical detection for breast using
blue dye [3], or radioisotopes [4], or both [5]. In
particular, in 1993 Alex and Krag described direct
localization of sentinel nodes with radioactive tracers
and a hand-held gamma probe [6].
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In conclusion, the sentinel lymph node status predicts
distant basin status, especially in early stages of the
disease. Basin involvement is less frequent in these
patients and surgery can be targeted to the appropriate
population [7].
Neoadjuvant chemotherapy
During the past 25 years, new concepts and discoveries
have dramatically influenced the therapeutic manage-
ment of breast cancer. The hypothesis formulated in the
1960s by Bernard Fisher contended that in most instances
`operable breast cancer is a systemic disease involving a
complex spectrum of host±tumour interrelations and that
variations in local±regional therapy are unlikely to affect
survival' [8]. This `paradigm' and the long-term results of
clinical trials [9, 10] have been able to modify the
traditional concepts of `radical' surgery for the treatment
of a `local' disease as the breast cancer.
In patients with high-risk tumours, surgery should be
considered an incorrect form of primary treatment and
only appropriate variations in systemic drug therapy are
likely to increase relapse free and total survival ratios
through the eradication of distant micrometastasis [11].
This adjuvant treatment is called neoadjuvant (also
primary, induction or perioperative) chemotherapy and
has become a common approach for the treatment of a
variety of neoplasms, including breast cancer [12±15].
It has been noted in animal models that the removal of
a primary tumour may increase the growth rate of
micrometastases. One possible explanation for this
phenomenon, based on angiogenesis, is that some
tumours have been shown to release factors that are
angiostatic, and thus limit the growth of metastases by
inhibiting new blood vessel formation [16, 17]. The
removal of the primary tumour and loss of angiostatic
factors, angiogenesis occurs in micrometastases which
can then progress. As the number of tumour cells
increases, the likelihood of chemoresistant clones being
present increases. NC could minimize this phenomenon.
One of the first trials in the NC of breast cancer was
initiated at the Milan Cancer Institute more than 20 years
ago as part of the multidisciplinary studies that were
designed for stage III disease [18]. Today, the long-term
value of systemic adjuvant therapy in patients with
advanced breast cancer is clearly established [19, 20].
There are several problems related to the use of NC in
patients with early breast cancer [21]. For instance,
accurate knowledge of pre-treatment pathological nodal
status is unavailable, thus one of the most significant
preoperative prognostic factor is unknown.
Neoadjuvant chemotherapy may be used if the tumour
response to chemotherapy prior to surgery needs to be
known or if breast conservation therapy is otherwise not
possible [12]. In our hospital, the number of patients
treated with NC has increased in recent years.
The aim of this study was to validate the SN
radioguided detection in these patients in order to apply
the technique in patients submitted to NC.
Patients, materials and methods
Seventy-six consecutive female patients with single breast
cancer who had not received surgery or radiotherapy
were included in the study. Written informed consent
was obtained from them all.
Patients were assigned to one of two groups, following
the usual hospital protocol. Group 1 consisted of 40
patients (mean age 52 years, range 36±69 years) who had
previously received NC (Table 1). Group 2 consisted of 36
patients (mean age 55 years; range 31±87 years) who have
not received any chemotherapy (Table 2). An injection of
tracer, 111 MBq (3 mCi) of 99Tcm-nanocolloid, was
administered peritumourally at four different points.
Each injection volume was 0.75 ml.
Scintigraphy
Five-min anterior and lateral (hanging breast) thoracic
projections including breast and axilla, were obtained at
2 h post-injection. A 57Co flood phantom was positioned
back to the patient to outline the anatomical contour and
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External, upper left quadrant 24 (60)
External, lower left quadrant 7 (17)
Internal, lower right quadrant 3 (7)











Ductal grade 1 1 (3)
Ductal grade 2 12 (30)
Ductal grade 3 24 (60)
Others 3 (7)
*n = 40; mean age, 52 years, range, 36±69 years.
help localize the sentinel node. Once the SN had been
detected its position was labelled on the skin using a
permanent ink marker.
Surgical localization
Patients underwent surgery the following day (18±24 h
post-injection). Intra-operative sentinel node localization
was performed using a GAMMED 2 gamma probe. Once
localized and removed from the patient, the SN was sent
to the histology department. In order to select the true
SN, the search of active ganglia continued until the
activity in the axillary area was negligible. All patients
underwent total axillary lymph node dissection.
Histology
The removed lymph nodes were paraffin-embedded
intact and lamellated into pieces approximately 1 cm in
size. Three HE stained sections were made per block.
Sections were analysed by two expert pathologists.
Immunohistochemistry using the CAM 5.2 antibody
was performed in 10 cases in order to detect micro-
metastases.
Results
Group 1 (n = 40)
Lymphoscintigraphy Axillary lymph nodes were seen in
29 patients. In 15 there was only one sentinel node. In the 14
remaining patients two or more lymph nodes were seen. In
seven patients a double lymph drainage was observed:
axillary and internal mammary chain (five patients),
axillary and intramammary (one patient) and axillary
and supraclavicular (one patient) (Fig. 1). Finally, in four
patients no sentinel node could be identified; in one of them
all the axillary lymph nodes were infiltrated. The mean
number of lymph nodes seen by scintigraphy was 1.7.
Surgery In 34 of the 36 patients in whom scintigraphy
showed the presence of at least one axillary SN, it could
be localized and drawn out at surgery. In the two
remaining patients no activity could be detected in the
axilla, or in other lymph chains.
Histology Histological analysis was performed in the 34
patients in whom an SN could be identified and drawn
out. Histopathology of the SN was compared to the
histopathology of all the other lymph nodes drawn out
by the surgeon.
In 14 patients the SN and all the other axillary lymph
nodes were not metastasized (14 true negatives). In 16
patients, both the SN and other axillary lymph node were
metastasized (16 true positives). In four of the 16 the SN
was the only node involved. In four patients the SN was
normal but metastases were found in other lymph nodes
(four false negative results). The false negative rate was
22% and negative predictive value was 78% (Table 3). In
two of the four false negatives cases tumour has
decreased in size by more than 50% post-NC.
Group 2 (n = 36)
Lymphoscintigraphy Axillary lymph nodes were seen in
22 cases. In 12 there was only one sentinel node. In the 10
remaining cases, two or more lymph nodes were seen. In
10 patients a double lymph drainage was observed to
axillary and internal mammary chain (nine cases) (Fig. 2)
and axillary and intramammary chain (one case). In one
case only the SN was localized in the internal mammary
chain and in another case only intramammary nodes
could be seen.
Finally, in two patients no sentinel node could be
identified; in one of them all the axillary lymph nodes
were infiltrated. The mean number of lymph nodes seen
by scintigraphy was 1.6.
Surgery In 29 out of the 32 patients in whom the
scintigraphy showed the presence of at least one axillary
SN, it could be localized and drawn out at surgery. In
two cases no activity could be detected in the axilla, or in
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External, upper left quadrant 17 (47)
External, lower left quadrant 8 (22)
Internal, lower right quadrant 4 (11)











Ductal grade 1 2 (5)
Ductal grade 2 20 (56)
Ductal grade 3 13 (36)
Others 1 (3)
*n=36; mean age, 55 years, range, 31±87 years.
other lymph chains and in one patient the sample taken
was found to be fatty tissue.
Histology Histological analysis was performed in the 29
patients in whom an SN could be identified and drawn
out. Histopathology of the SN was compared to the
histopathology of all the other lymph nodes drawn out
by the surgeon.
In 19 cases the SN and all the other axillary lymph
nodes were not metastasized (19 true negatives). In eight
cases, both the SN and other axillary lymph nodes were
metastasized (eight true positives). In four cases, the SN
was the only node involved. In two cases the SN was
normal but was found to metastasize in other lymph
nodes (two false negative). The false negative rate was 9%
and negative predictive value was 90% (Table 4).
Discussion
Scintigraphic and gamma probe localization of sentinel
node is a well-established method in patients with malign
melanoma [22, 23]. However, the situation is different in
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Table 3. Sentinel node and total axillary lymph node dissection
histology in patients treated with neoadjuvant chemotherapy
(Group 1).
Axillary lymph node dissection Sentinel node dissection Total
Positive SN Negative SN
Positive total 12 4 16
Negative total 4 14 18
Total 16 18 34
A
B
Fig. 2. Anterior (A) and lateral (B) views of a patient, showing
drainage to the intramammary chain. Time post-injection, 2 h.
A
B
Fig. 1. Anterior (A) and lateral (B) views of a patient, showing
drainage to the subclavicular area. Time post-injection, 2 h.
other solid tumours, especially in breast cancer, where
many factors, such as injection method, tracer and clinical
indications, are still to be standardized [7].
Small single tumours (T1, T2), in untreated (surgery or
radiotherapy) patients seem to be the more appropriate
for the application of this methodology, identifying the
SN and indicating selective lymphoscintigraphy, depend-
ing on the results of the histological study [24]. The
method has been widely applied to untreated patients.
Nevertheless, the influence of previous NC on SN
localization has not been fully investigated.
In our hospital, NC is largely used prior to surgery and
radiotherapy. In order to determine whether the large
number of patients included in our protocol could benefit
from this new methodology we decided to investigate
this field [25].
There were no significant differences in tumour size or
patients' ages between both groups. Our results show
differences in the number and distribution of SN
localization between the two groups studied. SNs were
limited to the axilla in 72% of Group 1 patients, and 58%
of Group 2 patients. The percentage of examinations in
which no SN could be identified was 10% in Group 1
and 5% in Group 2. The mean number of SNs localized
was quite similar: 1.7 and 1.6 in Groups 1 and 2,
respectively.
These results indicate the greater difficulties in
localizing SNs in patients submitted to NC, but the
frequency of other lymph pathways is more frequent in
untreated patients.
At surgery the efficacy was similar in both groups: the
SN could be localized and extracted in 94% and 91% of
Group 1 and Group 2 patients, respectively.
The more important point is the frequency of false
negative results (negative SN and the finding of other
lymph nodes that had metastasized). In Group 1, SNs
were falsely negative in four patients, which means a
false negative rate of 22% and a negative predictive value
of 78%. In three of the four patients the size of the tumour
had decreased significantly following chemotherapy.
In Group 2, the SN was falsely negative in only two
patients, resulting in a false negative rate of 9% and a
negative predictive value of 91%. These results agree
with published results by other authors [5, 26] and
support the use of this methodology in untreated
patients.
This large difference between treated and untreated
patients could be explained by changes in axillary lymph
drainage due to chemotherapy. If the true SN (the first to
receive drainage from the tumour) is metastasized,
probably this node would respond to chemotherapy as
does the primary tumour. In consequence, the lymph
node tissue would be replaced by fibrotic tissue (which
does not take up the colloid particles) and what the
scintigraphy and probe identifies as a sentinel node could
really be a second echelon. This false SN and other
axillary lymph nodes could be metastasized or not
depending on the evolution of the disease. The final
results would be an increase of skip metastasis.
According to these results, the scintigraphic and probe
localization of SNs cannot be recommended in breast
cancer patients if they have undergone neoadjuvant
chemotherapy.
One of the arguments against the use of NC is the
increasing difficulty in staging the patients, which is
essential for establishing a prognosis. One possible
solution could be ambulatory localization of the SN,
through a small axillary incision, prior to the commence-
ment of chemotherapy. This study is being carried out in
our department.
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